Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8% – What’s Next?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s share price traded up 10.8% on Thursday . The company traded as high as $54.48 and last traded at $55.6050. 279,959 shares were traded during mid-day trading, a decline of 73% from the average session volume of 1,043,011 shares. The stock had previously closed at $50.17.

Analyst Ratings Changes

Several equities research analysts have commented on GPCR shares. HC Wainwright cut their price objective on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, March 16th. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 20th. Jefferies Financial Group set a $125.00 price objective on Structure Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, BMO Capital Markets set a $145.00 price objective on Structure Therapeutics and gave the company an “outperform” rating in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.00.

Structure Therapeutics Trading Up 5.5%

The stock’s fifty day simple moving average is $66.17 and its 200 day simple moving average is $52.16. The company has a market cap of $3.75 billion, a price-to-earnings ratio of -66.96 and a beta of -1.16.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.14). On average, analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GPCR. Osaic Holdings Inc. grew its position in Structure Therapeutics by 101.9% in the second quarter. Osaic Holdings Inc. now owns 63,362 shares of the company’s stock worth $1,314,000 after acquiring an additional 31,972 shares during the period. Aberdeen Group plc raised its position in Structure Therapeutics by 46.1% in the third quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock valued at $16,432,000 after purchasing an additional 185,245 shares during the period. Jefferies Financial Group Inc. purchased a new stake in Structure Therapeutics in the third quarter valued at $4,770,000. Birchview Capital LP acquired a new position in shares of Structure Therapeutics in the 2nd quarter valued at $747,000. Finally, Private Capital Advisors Inc. purchased a new position in shares of Structure Therapeutics during the 3rd quarter worth $1,545,000. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.